Catalyst Pharmaceuticals (CPRX) EBT (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly EBT came in at $84.2 million in Q1 2026, up 18.16% YoY from $71.3 million in Q1 2025, and up 17.15% on a QoQ basis from $71.9 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) EBT (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of EBT data on file, last reported at $84.2 million in Q1 2026.
- Quarterly EBT rose 18.16% year-over-year to $84.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $296.5 million (up 14.7% YoY) and the FY2025 annual result came in at $283.5 million, up 31.1% from the prior year.
- EBT advanced to $84.2 million in Q1 2026, from $71.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of $84.2 million in Q1 2026 to a low of -$38.0 million in Q3 2023.
- A 5-year average of $46.1 million and a median of $48.5 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT tumbled 246.2% — and 2024, when it jumped 250.46%.
- Tracing CPRX's EBT over 5 years: stood at $33.0 million in 2022, then jumped by 41.5% to $46.7 million in 2023, then surged by 58.82% to $74.2 million in 2024, then decreased by 3.07% to $71.9 million in 2025, then climbed by 17.15% to $84.2 million in 2026.
- The last three EBT figures came in at $84.2 million (Q1 2026), $71.9 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 84.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.23 Mn |
| Dec 31, 2025 | 71.90 Mn |
| Sep 30, 2025 | 71.04 Mn |
| Jun 30, 2025 | 69.29 Mn |
| Mar 31, 2025 | 71.29 Mn |
| Dec 31, 2024 | 74.18 Mn |
| Sep 30, 2024 | 57.21 Mn |
| Jun 30, 2024 | 55.79 Mn |
| Mar 31, 2024 | 29.09 Mn |
| Dec 31, 2023 | 46.71 Mn |
| Sep 30, 2023 | -38.02 Mn |
| Jun 30, 2023 | 48.51 Mn |
| Mar 31, 2023 | 37.31 Mn |
| Dec 31, 2022 | 33.01 Mn |
| Sep 30, 2022 | 26.01 Mn |
| Jun 30, 2022 | 28.25 Mn |
| Mar 31, 2022 | 17.46 Mn |
| Dec 31, 2021 | 12.81 Mn |
| Sep 30, 2021 | 14.07 Mn |
| Jun 30, 2021 | 15.90 Mn |